Jump to section
To build neuroelectronic interfaces to cure brain disorders.
26% employee growth in 12 months
More than 35% of the population have been afflicted with brain disorders, costing around €800 billion per year in each of Europe and the USA. The drugs to treat those disorders make up around 20% of this, with patients suffering from additional side effects. Currently all brain interfaces are metal based, which are met with restrictions that limit therapeutic effect.
INBRAIN Neuroelectronic's bioelectrical implants technology uses the power of graphene, which has a unique blend of electrical and thermal conduction properties. Combined with machine learning software that delivers an adaptive neuromodulation therapy personalised for each patient, INBRAIN believe that this could be a faster and safer way of brain restoration, free of side effects.
INBRAIN Neuroelectronics have recently secured substantial funding which will be used to drive their first in-human clinical program. They aim to demonstrate the safety of graphene as the new standard of care for neurotechnology devices, which could be a revolutionary development for the industry.
Kirsty
Company Specialist at Welcome to the Jungle
Oct 2024
$48.8m
SERIES B
Oct 2023
$3.2m
CONVERTIBLE
Carolina Aguilar
(CEO)Formerly a Business Director and Manager for Medtronic.